Skip to content
value.today

Alimera Sciences

ALIMUnlisted company
$209 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$81 M
For year ending December-2023
Net income
$-20 M
-24.9% margin
SEC filing
Employees
—

Alimera Sciences in brief

Alimera Sciences is an unlisted company in the Pharmaceutical industry, based in Alpharetta, Georgia, USA. It was founded in 2003. In the year to December 2023 it had sales of $81 M and a net loss of $20 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Alimera Sciences

Alimera Sciences, Inc. was a biopharmaceutical sales company based in Alpharetta, Georgia that specialized in the commercialization and sales of prescription ophthalmic pharmaceuticals. The company's main selling focus was on diseases affecting the back of the eye, or retina.

In September, 2024, ANI Pharmaceuticals, Inc. announced that it had completed its purchase of the company.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Alimera Sciences timeline

4 events, 2003–2023
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2010
  5. 🔔
    · approximate
    Initial public offering on Nasdaq as ALIM
  6. 2023
  7. 💰
    Record revenue of $81 million
    FY2023, the highest of the 6 years on record.

Events of Alimera Sciences from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Alimera Sciences

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 16 September 2024 (Form 8-K).

Market cap history

$0 M$56 M$113 M$169 M$226 M20202021202220232024

World rank over time

▲ up 4,858 places since 2020
2020-01-01: #22523#22,52320202021-01-01: #23231#23,23120212022-01-07: #28973#28,97320222022-12-25: #30326#30,32620222023-07-30: #27921#27,92120232024-01-05: #17665#17,6652024

Rank in USA: #4,193 (Jan 2020) · #4,386 (Jan 2021) · #5,112 (Jan 2022) · #5,407 (Dec 2022) · #5,026 (Jul 2023) · #3,220 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-24.9%
Operating margin
-2.4%
Return on equity
-43.6%
Liabilities / assets
69.9%
Net debt
$33M
Revenue growth
+49.2%
R&D / revenue
20.6%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2016: revenue $34M, net income $-33M$34MFY16Fiscal year ending Dec 2017: revenue $36M, net income $-22M$36MFY17Fiscal year ending Dec 2018: revenue $47M, net income $-16M$47MFY18Fiscal year ending Dec 2019: revenue $54M, net income $-10M$54MFY19Fiscal year ending Dec 2020: revenue $51M, net income $-5M$51MFY20Fiscal year ending Dec 2021: revenue $59M, net income $-4M$59MFY21Fiscal year ending Dec 2022: revenue $54M, net income $-18M$54MFY22Fiscal year ending Dec 2023: revenue $81M, net income $-20M$81MFY23
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2023$81M+49.2%$-2M$-20M-24.9%
Dec 2022$54M-8.3%$-12M$-18M-33.5%
Dec 2021$59M+16.2%$-0M$-4M-7.4%
Dec 2020$51M-5.8%$-1M$-5M-10.5%
Dec 2019$54M+15.8%$-5M$-10M-19.4%
Dec 2018$47M+29.8%$-10M$-16M-35.2%
Dec 2017$36M+4.6%$-16M$-22M-61.3%
Dec 2016$34M—$-28M$-33M-96.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2023$-14M$0M$-15M$-0.84—
Dec 2022$-10M$0M$-10M$-2.59—
Dec 2021$-3M$1M$-4M$-0.66—
Dec 2020$-2M$1M$-3M$-1.04—
Dec 2019$-4M$0M$-4M$-2.19—
Dec 2018$-12M$0M$-12M$3.71—
Dec 2017$-13M$0M$-13M$-0.33—
Dec 2016$-25M$0M$-25M$-0.63—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2023: revenue $14M, net income $-5M$14MMar ’23Three months to Jun 2023: revenue $18M, net income $-10M$18MJun ’23Three months to Sep 2023: revenue $23M, net income $-1M$23MSep ’23Three months to Dec 2023 (from the annual report): revenue $26M, net income $-4M$26MDec ’23Three months to Mar 2024: revenue $23M, net income $-6M$23MMar ’24Three months to Jun 2024: revenue $27M, net income $-3M$27MJun ’24

Latest quarter to Jun 2024: revenue $27M (+53.9% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Alimera Sciences with the US Securities and Exchange Commission.

Annual results

Revenue
$81 M
Operating income
$-2 M
Net income
$-20 M

For year ending December-2023 · source: SEC filing

Balance sheet

Total assets
$154 M
Total liabilities
$107 M
Total equity
$46 M

As of December-2023

Insider trading at Alimera Sciences#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
54
since
Alimera Sciences: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David HollandChief Marketing Officer & SVPDisposal to the company-187,756——0Form 4
filed Peter J. Pizzo IIIDirectorDisposal to the company-500——0Form 4
filed Jason M. WernerChief Operating OfficerDisposal to the company-225,000——225,000Form 4
filed Philip AshmanPresident of Int'l OperationsDisposal to the company-118,274——0Form 4
filed Caligan Partners LP10% ownerOtherindirect-16.84 M——0Form 4
filed John SnisarenkoDirectorDisposal to the company-10,000——0Form 4
filed Richard S. Eiswirth Jr.President and CEODisposal to the company-324,018——0Form 4
filed Velan Capital Management LLC10% ownerDisposal to the companyindirect-9.43 M——0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Alimera Sciences#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q4 2023
$0M
Q4 2023

Stock splits: 15-for-1 split

Alimera Sciences share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q2 2023Q2 2023$0M
Q1 2023Q1 2023$0.3M

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Alimera Sciences scorecard#

Passes 4 of the 16 checks that could be worked out: strongest in growth (3 of 6), weakest in profitability (0 of 5). Fiscal year 2023.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth3 of 6
    • ✓Revenue grew in the newest year49.2%Revenue up 49.2% in fiscal 2023.
    • ✓Revenue up more than 5% a year over three years16.7%16.7% a year over the three years to fiscal 2023.
    • ✓Faster growth over three years than its peers' median16.7%16.7% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-0.84 vs -2.59Diluted EPS -0.84 in fiscal 2023 against -2.59 the year before (report's currency).
    • ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2023 against -$16 M in 2018.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2023.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2023.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2023.
    • ✗Operating margin above its peers' median-2.4%-2.4% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-158.8%-158.8% in fiscal 2023.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-2.4%-2.4% in fiscal 2023 against -1.0% in 2020.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.39 at the end of fiscal 2023.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-0.2×Operating income -0.2 times interest in fiscal 2023.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2023.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 2
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year265.3%Diluted shares up 265.3% in fiscal 2023.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • ✗Free cash flow covers dividends and buybacks-$15 MFree cash flow -$15 M against $0 M paid out in fiscal 2023.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Alimera Sciences: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Alimera Sciences: statements by fiscal year
PeriodTrendFY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014
Income statement
Revenue815459515447r3634228.4
Cost of revenue——————3.42.31.81.4
Gross profit7046524447423232217.0
Research and development1716149.7111113121512r
Selling and marketing2826232026—————
General and administrative1913131213r1513151412
Operating expenses72585244535249606040
Operating income−1.9−12−0.2−0.5−5.3−9.7−16−28−39−33
Interest expense and finance costs105.95.45.44.94.85.65.24.72.1
Income before tax−20−18−3.9−5.4−10−16−22−33−31−36
Income tax0.10.00.4−0.10.20.10.20.20.10.2
Net income attributable to shareholders−20−18−4.4−5.3−10−16−22−33−31−36
Earnings per share, basic-0.84-2.59-0.66-1.04-2.193.74r-0.33-0.63-0.69-0.91
Earnings per share, diluted-0.84-2.59-0.66-1.04-2.193.71r-0.33-0.63-0.69-0.91
Shares, weighted average (basic)267.06.6—4.84.7r67———
Shares, weighted average (diluted)267.06.65.14.84.7r67534440
Balance sheet
Cash and cash equivalents125.317119.41324313177
Receivables35201917191711149.80.9
Inventory1.91.62.72.71.42.41.50.41.61.7
Other current assets3.92.93.83.72.62.12.32.12.73.2
Current assets52294235333539474583r
Property, plant and equipment2.52.52.81.60.91.41.41.82.61.7
Right-of-use (leased) assets1.11.41.70.71.1—————
Other intangible assets979.01113151719212324
Total assets1544359515054607070109r
Accounts payable8.3108.77.57.16.45.95.04.05.0
Debt due within a year————00————
Current liabilities2240131212109.79.14010
Long-term debt————3938————
Lease liabilities (non-current)1.82.32.70.40.8—————
Total liabilities10763————————
Retained earnings−418−415−397−393−388−377−399−377−344−313
Shareholders' equity46−21−2.6−8.0−4.42.715r262650
Total liabilities and equity1544359515054607070109r
Shares outstanding527.06.95.75.04.7r69654544
Cash-flow statement
Depreciation and amortization8.72.72.62.72.62.62.72.82.60.7
Share-based compensation1.40.91.01.32.54.45.04.95.03.9r
Cash from operating activities−14−10.0−3.2−2.2−4.2−12−13−25−45−24
Capital expenditure−0.3−0.3−0.6−0.6−0.2−0.2−0.2−0.2−0.5−0.8
Intangible assets bought−75———————0−25
Cash from investing activities−76−0.3−0.6−0.6−0.2−0.2−0.2−0.2−0.5−26
Debt issued23——4.343400———
Shares issued2.40.1100.00.90.16.1281.038
Shares bought back−0.3—————————
Dividends paid—————————0
Cash from financing activities96−0.39.83.90.91.05.7r250.6115
Exchange-rate effect on cash0.1−0.7−0.70.7−0.2−0.20.5r−0.2−0.4−0.5
Change in cash6.8−115.31.8−3.6−11−6.9r−0.1−4664
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Alimera Sciences#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Delisting notice 1 · Taken over and delisted 1 · Change in control 2 · Acquisition or sale completed 2 · Directors and officers 13 · Material agreement 7 · Agreement ended 1 · New debt 3 · Unregistered share sale 4 · Shareholder rights changed 5 · Bylaws or fiscal year changed 4 · Shareholder vote 2 · Results announced 7

Alimera Sciences: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersAgreement endedShareholder rights changedBylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Material agreementResults announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Change in controlUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Directors and officersUnregistered share saleShareholder rights changedShareholder vote8-K
Directors and officers8-K
Acquisition or sale completedDirectors and officersMaterial agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Results announced8-K
Delisting noticeDirectors and officersMaterial agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Directors and officers8-K
Material agreementNew debt8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 16, 2024

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Alimera Sciences
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2023$81 MNo. 5$50 to $250 million16equity, optionsSEC
Apr 2021$10 MNo. 4$10 to $50 million1equitySEC
Jan 2014$38 MNo. 3$10 to $50 million21equitySEC
Oct 2012$40 MNo. 2$10 to $50 million—equity, optionsSEC
Aug 2009$5 MNo. 1$2 to $10 million25equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

FDA drug approvals: Alimera Sciences#

2 approved applications held; 1 approvals and 0 new uses in 2018.

Approvals held
2
New molecular entities
0
New uses approved
0
efficacy supplements
Generics
0
2 new drugs, 0 biologics
Alimera Sciences: latest FDA approvals
ApprovedDrugKind
2018-10-12YutiqFluocinolone Acetonide · NDA210331New drug (NDA)
2014-09-26IluvienFluocinolone Acetonide · NDA201923New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (ALIMERA SCIENCES INC), so they follow acquisitions

How Alimera Sciences compares in Pharmaceutical

  • Revenue$81 M · higher than 20% of 324
  • Net margin-24.9% · higher than 13% of 313
  • Revenue growth49.2% · higher than 90% of 107

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Alimera Sciences🇺🇸$209 M—-24.9%+49.2%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2023
Balance sheet:
As of December-2023
Profile updated:
Nov 14, 2026

Figures from SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Alimera Sciences? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Alimera Sciences's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Alimera Sciences? Suggest a correction